Loxo's FOMO

Why Loxo and Lilly struck a buyout deal so quickly

Loxo Oncology Inc. (NASDAQ:LOXO) management held advanced licensing discussions with four potential partners during 2018 for its LOXO-292 program targeting RET, but the company instead chose an uncontested takeout offer from Eli Lilly and Co. (NYSE:LLY) as the year came to a close.

The $8 billion acquisition came together quickly and quietly, according to an SEC document filed Thursday. Lilly delivered

Read the full 609 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE